Cosmos Health Inc. (COSM)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
CRITICAL DILUTION RISKDilution score: 78/100 (CRITICAL), 2.0 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 7.47% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
- COSM Continues to Surge Revenue Growth
- COSM Continues to Grow Business
- Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline
- Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
- Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units
- COSM Again Expands its Market and Accelerates its Growth
- Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Effect of a multivitamin and cocoa flavanol extract on changes in neurofilament light, N-terminal tau fragment, and oligomeric amyloid-β levels in COSMOS-clinic. — J Alzheimers Dis 2026 Sep 23 PMID 42775737
- Multivitamin supplementation and COVID-19 incidence and symptom severity in the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized trial. — Am J Clin Nutr 2026 Jul PMID 42385272
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Cosmos Health Inc..
Full COSM Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.